| Literature DB >> 29642374 |
Muneko Nishijo1,2, Hideaki Nakagawa3, Yasushi Suwazono4, Kazuhiro Nogawa5, Masaru Sakurai6, Masao Ishizaki7, Teruhiko Kido8.
Abstract
After 26 years, we followed up 7348 participants in a 1979-1984 health screening survey in the Jinzu River basin, the heaviest cadmium-polluted area in Japan. We assessed the associations of cadmium exposure levels and mortality from cancer and renal damage, indicated by records of proteinuria and glucosuria in the original survey. Mortality risks (hazard ratios) were analyzed using the Cox proportional hazards model, stratified by sex, after adjusting for age, smoking status, and hypertension, as indicated in the original survey records. In men, the adjusted hazard ratio for mortality from lung cancer was significantly lower in individuals residing in an area of historically high cadmium exposure and in subjects with a historical record of proteinuria, glucosuria, and glucoproteinuria. The risk of mortality from prostate cancer was borderline higher in cadmium-exposed men. In women, historical cadmium exposure was not associated with an increased risk of mortality from malignant neoplasms, but the adjusted hazard ratios for death from total malignant neoplasms or from renal and uterine cancers were significantly higher in exposed subjects with a historical record of proteinuria, glucosuria, and glucoproteinuria. These findings suggest that women residing in cadmium-polluted areas who exhibit markers of renal damage may be at risk of dying of cancer.Entities:
Keywords: cadmium; cancer; cause of death; environmental pollution; follow-up study; mortality
Year: 2018 PMID: 29642374 PMCID: PMC6027272 DOI: 10.3390/toxics6020023
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Age distribution of prevalence of urinary findings: positive cases, smokers and cases with a hypertensive history.
| Sex | Age | No (%) | Pro(+)/Glu(+)(%) | Smoking (%) | HT (%) | No (%) | Pro(+)/Glu(+)(%) | Smoking (%) | HT (%) |
|---|---|---|---|---|---|---|---|---|---|
| Control | Exposed | ||||||||
| Men | 50–59 | 383 (41.4) | 67 (17.5) | 267 (69.7) | 80 (20.9) | 1443 (42.9) | 283 (19.6) | 1028 (71.4) | 242 (16.8) |
| 60–69 | 318 (34.3) | 66 (20.8) | 186 (58.7) | 79 (24.8) | 1106 (32.9) | 247 (22.3) | 674 (61.2) | 263 (23.8) | |
| 70–79 | 179 (19.3) | 36 (20.1) | 85 (47.5) | 60 (33.5) | 623 (18.5) | 197 (31.6) | 319 (51.4) | 178 (28.6) | |
| ≥80 | 46 (5.0) | 9 (19.6) | 16 (34.8) | 10 (21.7) | 191 (5.7) | 80 (41.9) | 56 (29.8) | 53 (27.7) | |
| Total | 926 (100.0) | 178 (19.2) | 554 (59.9) | 229 (24.7) | 3363 (100.0) | 807 (24.0) | 2077 (62.0) | 736 (21.9) | |
| Women | 50–59 | 474 (40.4) | 37 (7.8) | 9 (1.9) | 97 (20.5) | 1613 (40.5) | 152 (9.4) | 94 (5.8) | 254 (15.7) |
| 60–69 | 372 (31.7) | 41 (11.0) | 8 (2.2) | 102 (27.4) | 1289 (32.3) | 237 (18.4) | 119 (9.3) | 308 (23.9) | |
| 70–79 | 231 (19.7) | 37 (16.0) | 5 (2.2) | 69 (29.9) | 883 (22.2) | 304 (34.4) | 80 (9.1) | 231 (26.2) | |
| ≥80 | 95 (8.1) | 18 (18.9) | 6 (6.4) | 28 (29.5) | 200 (5.0) | 108 (54.0) | 19 (9.6) | 54 (27.0) | |
| Total | 1172 (100.0) | 133 (11.3) | 28 (2.4) | 296 (25.3) | 3985 (100.0) | 801 (20.1) | 312 (7.9) | 847 (21.3) | |
Note, missing 1 control man, 13 exposed men, 4 control women and 11 exposed women from the smoking group, Pro(+)/Glu(+): proteinuria, glucosuria, and glucoproteinuria, No: number of subjects, HT: hypertension history.
Median and 90th and 95th percentiles of urinary Cd and positive rate (%) of urinary β2-microglobuline (≥1 mg/dL) in groups with different urinary findings.
| Sex | Urinary Findings | N | Urinary Cd (μg/L) | Urinary β2-MG(+) | |||
|---|---|---|---|---|---|---|---|
| Median | 90th per. | 95th per. | N | % | |||
| Men | Glu(+) and Pro(−) | 495 | 9.1 | 25.0 | 38.0 | 62 | 12.5 |
| Pro(+) and Glu(−) | 149 | 10.0 | 27.0 | 45.0 | 40 | 26.8 | |
| Pro(+) and Glu(+) | 159 | 12.0 | 22.0 | 28.9 | 120 | 75.5 | |
| Pro(+)/Glu(+) | 803 | 10.0 | 24.0 | 34.9 | 222 | 27.6 | |
| Women | Glu(+) and Pro(−) | 395 | 8.5 | 20.0 | 28.0 | 145 | 36.7 |
| Pro(+) and Glu(−) | 136 | 8.5 | 19.2 | 37.7 | 34 | 25.0 | |
| Pro(+) and Glu(+) | 267 | 7.7 | 17.9 | 22.0 | 242 | 90.6 | |
| Pro(+)/Glu(+) | 793 | 8.3 | 19 | 22.9 | 421 | 53.1 | |
Note, N: number of subjects, per.: percentile, β2-MG(+): beta2-microglobuline positive (≥1 mg/dL), Glu(+): glucosuria, Pro(+): proteinuria, Pro(+)/Glu(+): proteinuria, glucosuria, and glucoproteinuria.
Prevalence of renal damage indicated by proteinuria, glucosuria, and glucoproteinuria and Cd exposure.
| Analysis | Sex | Exposure | No | Pro(+)/Glu(+) (%) | Odds Ratio | (95%CI) | |
|---|---|---|---|---|---|---|---|
| Model 1 | Men | Control | 926 | 178 (19.2) | 1.00 | ||
| Exposed | 3363 | 807 (24.0) | 1.32 | (1.10, 1.59) | 0.003 | ||
| Model 2 | Men | Controls | 926 | 178 (19.2) | 1.00 | ||
| Non/Boderline | 1040 | 186 (17.9) | 0.92 | (0.74, 1.16) | 0.501 | ||
| Mild | 1231 | 275 (22.3) | 1.21 | (0.98, 1.49) | 0.085 | ||
| Moderate | 515 | 115 (22.3) | 1.18 | (0.90, 1.53) | 0.236 | ||
| High | 577 | 231 (40.0) | 2.83 | (2.24, 3.59) | 0.000 | ||
| Model 1 | Women | Control | 1172 | 133 (11.3) | 1.00 | ||
| Exposed | 3985 | 801 (20.1) | 2.21 | (1.80, 2.72) | 0.000 | ||
| Model 2 | Women | Controls | 1172 | 133 (11.3) | 1.00 | ||
| Non/Boderline | 1228 | 148 (12.1) | 1.13 | (0.87, 1.47) | 0.347 | ||
| Mild | 1508 | 258 (17.1) | 1.82 | (1.44, 2.30) | 0.000 | ||
| Moderate | 580 | 129 (22.2) | 2.67 | (2.02, 3.54) | 0.000 | ||
| High | 669 | 266 (39.8) | 6.20 | (4.81, 7.99) | 0.000 |
Note, covariates of logistic analysis: age, HT (hypertension) history, smoking, No: number of subjects, Pro(+)/Glu(+): proteinuria, glucosuria, and glucoproteinuria, CI: confident interval, p: p-value.
Mortality risk ratios for malignant neoplasms of Cd-exposed subjects compared with controls.
| Sex | Cancer | D | HR | D | HR | 95%CI |
|---|---|---|---|---|---|---|
| Controls | Exposed | |||||
| Men | Total | 174 | 1.00 | 653 | 0.98 | 0.8, 1.2 |
| Esophagus | 4 | 1.00 | 27 | 1.78 | 0.6, 5.1 | |
| Stomach | 57 | 1.00 | 180 | 0.83 | 0.6, 1.1 | |
| Colon, rectum | 16 | 1.00 | 64 | 1.05 | 0.6, 1.8 | |
| Liver | 16 | 1.00 | 58 | 0.96 | 0.6, 1.7 | |
| Gallbladder | 7 | 1.00 | 25 | 0.94 | 0.4, 2.2 | |
| Pancreas | 9 | 1.00 | 41 | 1.15 | 0.6, 2.4 | |
| Lung | 37 | 1.00 | 143 | 1.01 | 0.7, 1.5 | |
| Prostate | 5 | 1.00 | 21 | 1.05 | 0.4, 2.8 | |
| Bladder | 3 | 1.00 | 13 | 1.09 | 0.3, 3.8 | |
| Kidney/urinal tract | 2 | 1.00 | 8 | 1.09 | 0.2, 5.1 | |
| (Kidney) | 0 | - | 0 | - | - | |
| Lymph/blood forming organs | 7 | 1.00 | 31 | 1.15 | 0.5, 2.6 | |
| Women | Total | 114 | 1.00 | 437 | 1.05 | 0.9, 1.3 |
| Esophagus | 0 | - | 4 | - | - | |
| Stomach | 33 | 1.00 | 98 | 0.83 | 0.6, 1.2 | |
| Colon, rectum | 8 | 1.00 | 66 | 2.28 | 1.1, 4.8 * | |
| Liver | 5 | 1.00 | 27 | 1.43 | 0.5, 3.7 | |
| Gallbladder | 8 | 1.00 | 46 | 1.62 | 0.8, 3.4 | |
| Pancreas | 14 | 1.00 | 34 | 0.67 | 0.4, 1.3 | |
| Lung | 19 | 1.00 | 44 | 0.63 | 0.4, 1.1 | |
| Breast | 4 | 1.00 | 14 | 0.92 | 0.3, 2.8 | |
| Uterus | 3 | 1.00 | 15 | 1.44 | 0.4, 5.0 | |
| Ovary | 2 | 1.00 | 9 | 1.31 | 0.3, 6.1 | |
| Bladder | 2 | 1.00 | 4 | 0.62 | 0.1, 3.4 | |
| Kidney and urinal tract | 1 | 1.00 | 8 | 2.16 | 0.3, 17.4 | |
| (Kidney) | 0 | - | 4 | - | - | |
| Lymph/blood-forming organs | 5 | 1.00 | 27 | 1.39 | 0.5, 3.6 | |
Note, No: number of subjects, D: number of deaths, HR: hazard ratio, CI: confident interval, *: p < 0.05.
Mortality risk ratios for cancer in three exposed male groups compared with men living in the areas with borderline exposure in the Cd-exposed Jinzu River basin.
| Mortality | D | HR | D | HR | 95%CI | D | HR | 95%CI | D | HR | 95%CI |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposure Levels | Non/Border | Mild | Moderate | High | |||||||
| No | 1040 | 1231 | 515 | 577 | |||||||
| Total | 202 | 1.00 | 251 | 1.02 | 0.84, 1.23 | 107 | 1.12 | 0.88, 1.42 | 93 | 0.79 | 0.61, 1.01 # |
| Esophagus | 13 | 1.00 | 9 | 0.62 | 0.26, 1.48 | 4 | 0.53 | 0.15, 1.90 | 1 | 0.16 | 0.02, 1.23 |
| Stomach | 39 | 1.00 | 76 | 1.58 | 1.06, 2.36 | 29 | 1.62 | 0.99, 2.64 | 36 | 1.61 | 1.00, 2.57 * |
| Colon, rectum | 22 | 1.00 | 24 | 0.90 | 0.50, 1.62 | 10 | 1.02 | 0.48, 2.17 | 8 | 0.61 | 0.26, 1.45 |
| Liver | 20 | 1.00 | 20 | 0.82 | 0.44, 1.52 | 5 | 0.42 | 0.14, 1.23 | 13 | 1.08 | 0.52, 2.21 |
| Gallbladder | 8 | 1.00 | 6 | 0.58 | 0.20, 1.68 | 7 | 1.77 | 0.64, 4.90 | 4 | 0.79 | 0.24, 2.63 |
| Pancreas | 12 | 1.00 | 17 | 1.11 | 0.53, 2.32 | 7 | 1.19 | 0.47, 3.02 | 5 | 0.54 | 0.17, 1.67 |
| Lung | 50 | 1.00 | 58 | 0.96 | 0.65, 1.42 | 21 | 0.91 | 0.54, 1.52 | 14 | 0.53 | 0.29, 0.96 * |
| Prostate | 7 | 1.00 | 6 | 0.79 | 0.25, 2.46 | 4 | 1.30 | 0.37, 4.63 | 4 | 0.79 | 0.20, 3.19 |
| Bladder | 5 | 1.00 | 4 | 0.63 | 0.17, 2.36 | 3 | 1.18 | 0.28, 4.95 | 1 | 0.34 | 0.04, 2.90 |
| Kidney/urinal tract | 2 | 1.00 | 3 | 2.22 | 0.23, 21.3 | 2 | 3.79 | 0.34, 41.9 | 1 | 1.56 | 0.10, 25.2 |
| (Kidney) | 0 | - | 0 | - | - | 0 | - | - | 0 | - | - |
| Lymph/blood-forming organs | 10 | 1.00 | 12 | 0.97 | 0.42, 2.25 | 5 | 1.00 | 0.34, 2.94 | 4 | 0.67 | 0.21, 2.16 |
Note, No: number of subjects, D: number of deaths, HR: hazard ratio, CI: confident interval, #: p < 0.1, *: p < 0.05.
Mortality risk ratios for cancer in three exposed female groups compared with women living in the areas with borderline exposure in the Cd-exposed Jinzu River basin.
| Mortality | D | HR | D | HR | 95%CI | D | HR | 95%CI | D | HR | 95%CI |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exposure levels | Non/Border | Mild | Moderate | High | |||||||
| No | 1228 | 1508 | 580 | 669 | |||||||
| Total | 144 | 1.00 | 167 | 0.98 | 0.77, 1.23 | 56 | 0.84 | 0.61, 1.16 | 70 | 0.99 | 0.74, 1.34 |
| Esophagus | 1 | 1.00 | 1 | - | - | 1 | - | - | 1 | - | - |
| Stomach | 32 | 1.00 | 33 | 0.91 | 0.55, 1.51 | 9 | 0.66 | 0.31, 1.40 | 24 | 1.50 | 0.87, 2.62 |
| Colon, rectum | 24 | 1.00 | 21 | 0.72 | 0.40, 1.30 | 10 | 0.91 | 0.43, 1.92 | 11 | 0.89 | 0.43, 1.84 |
| Liver | 7 | 1.00 | 13 | 1.90 | 0.67, 5.41 | 4 | 1.16 | 0.28, 4.85 | 3 | 0.73 | 0.14, 3.75 |
| Gallbladder | 11 | 1.00 | 21 | 1.43 | 0.64, 3.20 | 9 | 2.01 | 0.80, 5.07 | 5 | 1.07 | 0.36, 3.21 |
| Pancreas | 12 | 1.00 | 12 | 0.88 | 0.39, 2.01 | 4 | 0.59 | 0.17, 2.13 | 6 | 1.10 | 0.40, 2.99 |
| Lung | 19 | 1.00 | 19 | 0.90 | 0.47, 1.72 | 1 | 0.12 | 0.02, 0.90 * | 5 | 0.48 | 0.16, 1.43 |
| Breast | 5 | 1.00 | 3 | 0.56 | 0.12, 2.49 | 5 | 2.32 | 0.62, 8.65 | 1 | 0.45 | 0.05, 4.02 |
| Uterus | 5 | 1.00 | 6 | 1.25 | 0.30, 5.25 | 1 | 0.66 | 0.07, 6.35 | 3 | 1.83 | 0.37, 9.14 |
| Ovary | 5 | 1.00 | 2 | 0.30 | 0.06, 1.53 | 1 | 0.40 | 0.05, 3.39 | 1 | 0.39 | 0.05, 3.36 |
| Bladder | 1 | 1.00 | 3 | 2.35 | 0.24, 22.8 | 0 | - | - | 0 | - | - |
| Kidney/urinal tract | 1 | 1.00 | 4 | 3.03 | 0.34, 27.2 | 2 | 4.10 | 0.37, 45.3 | 1 | 1.97 | 0.12, 31.7 |
| (Kidney) | 1 | 1.00 | 2 | 1.58 | 0.14, 1.75 | 0 | - | - | 1 | 2.30 | 0.14, 38.2 |
| Lymph/blood-forming organs | 9 | 1.00 | 8 | 0.70 | 0.27, 1.83 | 5 | 0.91 | 0.28, 2.97 | 5 | 1.07 | 0.36, 3.20 |
Note, No: number of subjects, D: number of deaths, HR: hazard ratio, CI: confident interval, *: p < 0.05.
Adjusted hazard ratios for cancer in subjects with proteinuria, glucosuria, and glucoproteinuria, compared with subjects without urinary findings living in the exposed area.
| Sex | Cancer | D | HR | D | HR | 95%CI |
|---|---|---|---|---|---|---|
| No Findings | Proteinuria and/or Glucosuria | |||||
| Men | Total | 522 | 1.00 | 130 | 0.87 | 0.71, 1.06 |
| Esophagus | 20 | 1.00 | 7 | 1.13 | 0.45, 2.86 | |
| Stomach | 142 | 1.00 | 38 | 0.95 | 0.66, 1.37 | |
| Colon, rectum | 53 | 1.00 | 10 | 0.73 | 0.37, 1.43 | |
| Liver | 42 | 1.00 | 16 | 1.44 | 0.80, 2.59 | |
| Gall bladder | 21 | 1.00 | 4 | 0.68 | 0.23, 1.98 | |
| Pancreas | 33 | 1.00 | 8 | 0.91 | 0.42, 1.98 | |
| Lung | 121 | 1.00 | 22 | 0.62 | 0.39, 0.98 * | |
| Prostate | 13 | 1.00 | 8 | 1.59 | 0.60, 4.25 | |
| Bladder | 11 | 1.00 | 2 | 0.59 | 0.13, 2.71 | |
| Kidney/urinal tract | 5 | 1.00 | 3 | 2.39 | 0.52, 10.9 | |
| (Kidney) | 0 | 1.00 | 0 | - | - | |
| Lymph/blood-forming organs | 24 | 1.00 | 7 | 1.02 | 0.44, 2.39 | |
| Women | Total | 339 | 1.00 | 97 | 1.49 | 1.17, 1.89 * |
| Esophagus | 2 | 1.00 | 2 | 1.82 | 0.15, 21.7 | |
| Stomach | 77 | 1.00 | 21 | 1.19 | 0.71, 1.98 | |
| Colon, rectum | 55 | 1.00 | 11 | 0.87 | 0.44, 1.70 | |
| Liver | 24 | 1.00 | 3 | 0.60 | 0.14, 2.61 | |
| Gallbladder | 36 | 1.00 | 10 | 1.75 | 0.84, 3.65 | |
| Pancreas | 25 | 1.00 | 9 | 1.99 | 0.89, 4.44 # | |
| Lung | 35 | 1.00 | 9 | 1.40 | 0.65, 3.00 | |
| Breast | 11 | 1.00 | 3 | 2.21 | 0.59, 8.28 | |
| Uterus | 10 | 1.00 | 5 | 3.85 | 1.16, 12.8 * | |
| Ovary | 7 | 1.00 | 2 | 1.58 | 0.31, 8.02 | |
| Bladder | 4 | 1.00 | 0 | - | - | |
| Kidney and urinal tract | 3 | 1.00 | 5 | 10.1 | 2.29, 44.5 * | |
| (Kidney) | 2 | 1.00 | 2 | 7.71 | 1.05, 56.8 * | |
| Lymph/blood-forming organs | 20 | 1.00 | 6 | 1.98 | 0.77, 5.09 | |
Note, No (urinary) findings: nether proteinuria nor glucosuria, No: number of subjects, D: number of deaths, HR: hazard ratio, CI: confident interval, #: p < 0.1, *: p < 0.05.